Status:
COMPLETED
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
Lead Sponsor:
Carlos Tornero
Conditions:
Covid-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to asses the efficacy of the Gammacore device reducing the need for mechanical ventilation in patients diagnosed of Covid-19
Eligibility Criteria
Inclusion
- Has been tested positive or suspected/presumed positive for CoViD-19
- Patients with cough, shortness of breath or respiratory compromise (RR\>24/min, increased work of breathing.)
- O2 Saturation less than or equal to 96% on room air or sensation
- Agrees to use the gammaCore®-Sapphire device as intended and to follow all of the requirements of the study including recording required study data
- Patient is able to provide signed and witnessed Informed Consent
Exclusion
- On home/therapy oxygen (i.e. for COPD patients) at baseline prior to development of CoViD-19
- Is already enrolled in a clinical trial using immunotherapeutic regimen for CoViD-19
- Already gammaCore for other medical conditions
- A history of aneurysm, intracranial hemorrhage, brain tumors, or significant head trauma
- Known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (eg, bruits or history of transient ischemic attack or cerebrovascular accident), congestive heart failure, known severe coronary artery disease, or recent myocardial infarction
- Uncontrolled high blood pressure (\>140/90)
- Current implantation of an electrical and/or neurostimulator device, including but not limited to a cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant
- Current implantation of metal cervical spine hardware or a metallic implant near the gammaCore stimulation site
- Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self-assessments is compromised (e.g. homeless, developmentally disabled and prisoner)
- Compromised access to peripheral veinous for blood)
- Pregnant women
Key Trial Info
Start Date :
April 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 17 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04368156
Start Date
April 20 2020
End Date
February 17 2021
Last Update
January 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010